AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05825105 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-Rich Plasma
Description: The PRP will be prepared using a single centrifugation process. Approximately 30 ml of peripheral blood will be drawn and collected into a vacutainer tubes with sodium citrate anticoagulant 0.129 mol/l (3.8%). The tubes will then be centrifuged at 900 RPM for 12 minutes at room temperature in a benchtop centrifuge. We will separate the lower third of the plasma fraction from all tubes with a syringe and needle, taking care to avoid the leukocyte layer. The PRP will be refrigerated at 4°C for no less than 1 hour. We will not use any exogenous factors to stimulate the platelet activation process. The periauricular skin surface will be disinfected with a povidone iodine solution, and an intra-articular local anesthetic with 1% lidocaine will be applied. A 21-gauge needle will be placed at the point of application. Finally, PRP will be injected into the joint, and the needle will be removed.
Study NCT06569836 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 12-week intervention
Description: Rehabilitation Exercise Plan Week 1-4 For No Symptom Group: Therapeutic home exercise prescription(2 sessions, 60 minutes per session) For Mild \& Moderate Group: Rehabilitation Plan provided by Physiotherapist (4 sessions, 60 minutes per session)~Enhancement of Self-Management Capacity Week 5-8 For No Symptom Group: Educational Workshops provided by Physiotherapist (2 sessions, 60 minutes per session) For Mild \& Moderate Group: Self-management group provided by Social Worker (4 sessions, 60 minutes per session)~Exercise Maintenance Week 9-12 For No Symptom Group: Mobilized Intervention (2 sessions, 60 minutes per session) For Mild \& Moderate Group: Exercise Maintenance provided by Exercise Mentor (4 sessions, 60 minutes per session)
Study NCT04705246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: The goal of the psychoeducation session is to provide insight in the hyperacusis symptoms, take away the fear of external noises, and encourage exposure to noise.
Study NCT05358496 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Data collection
Description: Clinical data collection
Study NCT06113952 — intervention group
Intervention type: DEVICE
Intervention: Sharps bin to collect used needles/injections
Description: Enrolled participants will be provided with a Smart Sharps Bin. The bin will collect used needles over a period of 12 months starting from enrollment.
Study NCT06569836 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 12-week attention control
Description: The attention and waitlist control group will have weekly educational and virtual workshops for 12 weeks. Three topics will be covered, including online exercise class, cognitive training, leisure and recreational activities. Each session will be 30-45 minutes and each topic last for four weeks. Participants could access the virtual sessions by their electronic devices.
Study NCT05586204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eligibility reminder
Description: Patients will receive a reminder of their eligibility for the bivalent COVID-19 booster
Study NCT05614037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felodipine sustained release tablets (trade name: plendil®)
Description: Reference preparation (R) : Felodipine sustained release tablets (trade name: plendil ®) Specification: 5 mg Batch number: 2204 a11 Content: 99.1% Valid until March 2025 Storage conditions: below 25℃ Manufacturer: AstraZeneca AB Supplier: Overseas Pharmaceuticals, Ltd. Usage: Oral, 1 tablet at a time, once a day. Take it before bed and swallow it with water. Do not break, press or chew the pill.
Study NCT05614037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Felodipine Controlled Release Tablets
Description: Test preparation (T) :Felodipine Controlled Release Tablets Specification: 5 mg Batch number: 22090301 Content: 100.8% Valid until: September 2024 Storage conditions: sealed, room temperature (10\~30℃) Manufacturer: Overseas Pharmaceuticals, Ltd. Supplier: Overseas Pharmaceuticals, Ltd. Usage: Oral, 1 tablet at a time, once a day. Take it before bed and swallow it with water. Do not break, press or chew the pill.
Study NCT05586204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Link to a narrow set of vaccine venues
Description: The reminder will encourage people to claim their dose today by booking an appointment. It will contain a link to schedule a booster appointment at UCLA Health and a link to CVS pharmacy
Study NCT06216392 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GR1802 injection
Description: 150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
Study NCT06216392 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
Study NCT05692661 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: proton plus carbon ion radiotherapy
Description: CTV1: whole breast, 40.05Gy(RBE) in 15 fractions with proton ion therapy; CTVboost: Tumor bed, carbon ion dose escalation study with four dose levels \[10.2Gy(RBE)/3Fx,10.8Gy(RBE) /3Fx,11.4Gy(RBE)/3Fx and 12Gy(RBE)/3Fx \].
Study NCT04212585 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serology test
Description: Serology for Helicobacter pylori (immunoglobulin G for all sites, immunoglobulin M optional, immunoglobulin A optional) will be collected from all participants. 90 samples (immunoglobulin G, immunoglobulin M and immunoglobulin A) at least needed from each site.~Stool antigen for Helicobacter pylori
Study NCT05299099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C006 inj.
Description: IN-C006 will be injected continuously for 3 days.
Study NCT05299099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RCN301
Description: RCN301 will be injected continuously for 3 days.
Study NCT05766371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT05766371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: Given IV
Study NCT06565195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3962681
Description: IT injection
Study NCT06565195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IT injection
Study NCT06084195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample and tissue sample
Description: During the surgery :~* Tissus sample : primary tumor and metastasis~* blood sample : 3 EDTA tubes~* ex vivo MRI data
Study NCT06008964 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ylang Ylang oil with inhalation
Description: Ylang Ylang OIL WILL BE INHALED
Study NCT06008964 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lavender oil with inhalation
Description: LAVENDER OIL WILL BE INHALED
Study NCT05357872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: deep anesthesia depth
Description: The anesthesiologist adjusted the intravenous speed of remifentanil and propofol to maintain the bispectral index (BIS, BIS monitor; Aspect Medical System, Newton, MA) between 40-50 and 50-60 during the operation.
Study NCT05357872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: light anesthesia depth
Description: The anesthesiologist adjusted the intravenous speed of remifentanil and propofol to maintain the bispectral index (BIS, BIS monitor; Aspect Medical System, Newton, MA) between 40-50 and 50-60 during the operation.
Study NCT05190042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cotinuous suture
Description: Cotinuous suture using surgery thread
Study NCT05190042 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clips
Description: Hemostatic clips
Study NCT05684068 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gum Graft Placed on Denuded Bone
Description: The provider will administer local anesthesia into the subject's gum in order to numb both the subject's donor and recipient areas for gum grafts. Next, the provider will use a surgical blade to dissect the gum graft from the subject's donor site. At the subject's recipient gum recession defect site, the provider will remove all of the subject's tissue, so that the bone is fully exposed before placing a gum graft from the donor site. Afterward, the provider will place sutures in the subject's recipient site in order to promote healing/re-growth.
Study NCT04521647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants will receive two nicotine concentrations via e-cigarettes. Each exposure will be 10 3-sec puffs and ad libitum use
Study NCT06452355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KOKO Device
Description: The intrauterine rolling drain is extended into the uterus, where low pressure vacuum is applied to the uterus through the fabric intrauterine rolling drain. The KOKO™ device utilizes this vacuum to remove excess blood and compress the uterus reducing further blood loss.
Study NCT06165497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation practices
Description: Participants will listen to recordings of short meditation practices drawn from the Healthy Minds Program.
Study NCT05684068 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gum Graft Placed on Split Thickness Periosteal Bed Preparation
Description: The provider will administer local anesthesia into the subject's gum in order to numb both the subject's donor and recipient areas for gum grafts. Next, the provider will use a surgical blade to dissect the gum graft from the subject's donor site. At the subject's recipient gum recession defect site, the provider will dissect some of the tissue at the subject's recipient site but still keep a small layer of tissue at the subject's recipient site before placing a gum graft from the donor site. Afterward, the provider will place sutures in the subject's recipient site in order to promote healing/re-growth.
Study NCT05586204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Link to a broad set of vaccine venues
Description: The reminder will encourage people to claim their dose today by booking an appointment. It will contain a link to schedule a booster appointment at UCLA Health and a link to vaccine.gov (where people can find a wide set of local pharmacies that carry the bivalent booster).
Study NCT06432335 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: E-Socket Monitoring
Description: Limb-socket motion data is collected during participant take-home use. Bimonthly telephone interviews are conducted to assess participant residual limb health status. Analysis is conducted to determine if limb motions and activity changes precede limb health changes.
Study NCT05637788 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT Scan Radiomics Features Extraction
Description: Extraction of CT radiomics data through AI
Study NCT05164627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: patients will receive Dexmedetomidine infusion (0.2 mcg/kg/hr) from the start of the surgery till the end of it.
Study NCT05164627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulphate
Description: patients will receive Magnesium infusion (10 mg/kg/hr) from the start of the surgery till the end of it.
Study NCT05164627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: After patient arrival at the PACU, Paediatric Anaesthesia Emergence Delirium (PAED) scale ,Ramsay sedation scores (RSS), emergence agitation, HR, and mean arterial blood pressure (MAP) were recorded every 5 min during the first 30 min, then every 10 min for the remaining 30 min of the recovery room stay. Patients were then transferred to the ward. All postoperative observations and scores were performed by the same anesthesiologist who was blinded to the group assignment
Study NCT05260827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heated tobacco product
Description: Sham heated tobacco product
Study NCT04996251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Injection
Description: 0.25% Bupivacaine being used as local anesthetic to inject into incision sites of tracer sites during a laparoscopic/robotic-assisted sacrocolpopexy
Study NCT06165497 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Internet-as-usual
Description: Participants will be instructed to use the internet as they typically do.
Study NCT05586204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doctors' recommendation and value of vaccine
Description: The reminder will contain information about the value of the bivalent booster and doctors' recommendation to get it
Study NCT06097416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant Chemoradiotherapy
Description: 5-FU is a fluoropyrimidine antimetabolite considered to act primarily as an inhibitor of thymidylate synthase. 5-FU is supplied as a colourless-to-faint yellow solution in 10-mL single use vials. Each 10 mL of solution contains 500 mg 5-FU, with pH adjusted to approximately 9.2 with sodium hydroxide.~The CRT regimen consists of the standard algorithms: a total of 5400-5600 cGy of radiation (4500 cGy to the pelvis, with an integrated boost to the primary tumour and involved nodes of 500 cGy followed by an option boost to the primary tumour and involved nodes) delivered in 27-28 fractions, respectively, of 180-200 cGy each over a 5-6 week period.
Study NCT06097416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Total Neoadjuvant Therapy
Description: 5-FU is a fluoropyrimidine antimetabolite considered to act primarily as an inhibitor of thymidylate synthase. 5-FU is supplied as a colourless-to-faint yellow solution in 10-mL single use vials. Each 10 mL of solution contains 500 mg 5-FU, with pH adjusted to approximately 9.2 with sodium hydroxide.~Oxaliplatin is an organoplatinum complex in which the platinum atom is complexed with 1,2- diaminocyclohexane with an oxalate ligand as a leaving group. Platinum content is 48.1% to 50.1%.~All patients received the same chemotherapy (FOLFOX) and long-course chemoradiotherapy (50.4 Gy in 28 fractions) before surgery.
Study NCT05834244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given by IV (vein)
Study NCT04999800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, an stomach cancer
Study NCT04999800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib is an oral small molecule multi-target receptor tyrosine kinase inhibitor
Study NCT05670678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: a2 growing up stage 3 formula puls lactoferrin supplement
Description: The participants in this group will consume 4-5 scoops (8.5g/scoop) of the assigned formula each time, and 4 times per day
Study NCT05670678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Enfinitas growing up stage 3 formula
Description: The participants in this group will consume 4 scoops (10g/scoop) of the assigned formula each time, and 3 times per day
Study NCT04566276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChulaCov19 vaccine
Description: SARS-Cov2 Wild-type S-spike mRNA/ lipid nanoparticle (LNP) vaccine
Study NCT04566276 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Saline
Study NCT06121739 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Mental Health Literacy Program
Description: The workshop has a participant-oriented character, seeking to apply the more theoretical contents to the local school context. It has four units and a total of nine modules, each lasting 90 or 120 minutes, with reference material on an educational platform. The topics are : 1) the person behind the role of educator; 2) the school community and its influence on the healthy development of students; 3) the expected development and its alterations in the different evolutionary stages; 4) common and differential factors of child and adolescent mental health disorders; 5) Stigma in Mental Health; 6) screening, the first care, and use of devices for the prevention and treatment of mental health disorders in children and adolescents.
Study NCT04910204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FES Therapy combined with task-specific training (FEST+TST)
Description: The FEST+TST protocol consists of a 1-hour session, 3 to 5 days a week, for up to 12 weeks (40 sessions total) in addition to conventional occupational and physical therapies according to the standard of care.
Study NCT05834244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO
Study NCT05834244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK Cells
Description: Given by IV (vein)
Study NCT05214521 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: digital interactive technology Smart glove SensoRehab
Description: Participants will receive rehabilitation program including sessions on the Smart glove SensoRehab (SGSR) system. The program for IS patients includes 10 sessions with the SGSR: 15-30 minutes once a day for the affected hand, 2 weeks.
Study NCT06378281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified teach-to-goal informed consent
Description: Enhanced procedure to improve informed consent in vulnerable populations.
Study NCT06215326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: moderate-intensity continuous training
Description: Participants in MICT group will need to additional complete a total of 12 supervised training sessions in 2-3 weeks.After a warm-up of 5 minutes at 50% at peak WR, the patient start exercising at 60%-70% peak WR for 30-40 minutes (four 5-8 minutes sets, with a 2-min rest in between), and then the patients cooled down for 5 minutes at 50% peak WR. Moderate-intensity exercise training intensity control at 55-74% HRmax or 40-69% VO2peak or PRE12-13 as recommended by guidelines.
Study NCT06215326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high-intensity interval training
Description: Participants in HIIT group will need to additional complete a total of 12 supervised training sessions in 2-3 weeks.After a 5-minute warm-up at 50% at peak WR, the patients complete 20 series of vigorous-intensity sprint (80%-100% peak WR for 30-60s) separated by a low-intensity recovery (30% peak WR or completely rest for 15s), and then the patients cooled down for 5 minutes at 50% peak WR. Participants will begin training at a relatively moderate intensity (60%-65% peak WR) for the first 3 sessions and gradually increase to the target intensity beginning on the 4th session. Intensity control of high-intensity exercise training at 75-90% HRmax or 70-85% VO2peak or PRE14-16 as recommended by guidelines.
Study NCT06201949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Articaine infiltration technique
Description: infiltration will be performed with articaine and epinephrine 1/100 000 (Artinibsa, Inibsa, Barcelona, Spain) for all patients on their second pri-mary molar. The needle tip was placed in the buccal vestibule and then directed to the apex of the tooth and about one-third to one-fourth of the cartridge will be slowly discharged
Study NCT06201949 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Articaine nerve block technique
Description: this technique will be performed with articaine and epinephrine 1/100 000 for all patients on their second primary molar with conventional technique inferior alveolar nerve block. The thumb will be placed on the occlusal surface of intended side and protruded toward the inner oblique ridge of ramus and then placed in touch with retromolar pad. The syringe will be directed between the two mandibular primary molars of opposite side and the needle will be pushed forward until hitting the bone, then the injection will be slowly done. After three to five minutes, treatment will be started, after numbness in the lower lip is achieved
Study NCT05283421 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Estrogen
Description: Women will receive active estrogen treatment or placebo prior to the colposcopic examination
Study NCT05283421 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Women will receive active estrogen treatment or placebo prior to the colposcopic examination
Study NCT06275386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel Drug-coated balloon
Description: Percutaneous coronary intervention of the actual CTO body with a paclitaxel drug-coated balloon.
Study NCT04879966 — intervention group
Intervention type: DRUG
Intervention: Infliximab
Description: Infliximab was used as induction therapy in UC patients, the maintenance treatment was decided by the researcher
Study NCT04879966 — intervention group
Intervention type: DRUG
Intervention: Corticosteroid
Description: Corticosteroids was used as induction therapy in UC patients, the maintenance treatment was decided by the researcher
Study NCT06166966 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flipped Education Model
Description: The effect of the Inside Out Education Model on the course success of nursing students.
Study NCT06023706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin 179 Mg Cutaneous Patch
Description: 1 patch applied once for 1 hour
Study NCT06023706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capsaicin low concentration patch (capsaicin 0,04%, 3,2 mg/cm2)
Description: 1 patch applied once for 1 hour
Study NCT04987502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: 8 sessions of virtual reality with 3D audio and visual rendering
Study NCT04987502 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: counselling, relaxation techniques, sound enrichment